DOTATATE is a somatostatin analog used as a peptide receptor radionuclide therapy (PRRT) agent to treat neuroendocrine tumors by targeting somatostatin receptors on tumor cells for precise radiopharmaceutical… Read more
DOTATATE is a somatostatin analog used as a peptide receptor radionuclide therapy (PRRT) agent to treat neuroendocrine tumors by targeting somatostatin receptors on tumor cells for precise radiopharmaceutical delivery. This category encompasses the parent drug along with its related impurities, such as N-nitroso derivatives, and specific metabolites essential for rigorous pharmaceutical analysis. Laboratories utilize these high-quality reference standards for comprehensive impurity profiling, method validation, and stability testing. By providing traceable materials for analytical characterization, these compounds enable researchers to ensure the accuracy of release testing and quality control procedures during the development and manufacturing of this therapeutic agent. Utilizing these specialized standards supports compliance with regulatory requirements and confirms the consistency of the radiopharmaceutical product throughout its shelf life.